COMPASS Pathways plc (NASDAQ:CMPS) Shares Acquired by Sio Capital Management LLC

Sio Capital Management LLC raised its stake in shares of COMPASS Pathways plc (NASDAQ:CMPS - Free Report) by 211.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 914,639 shares of the company's stock after purchasing an additional 621,222 shares during the period. COMPASS Pathways accounts for 2.3% of Sio Capital Management LLC's holdings, making the stock its 15th biggest position. Sio Capital Management LLC owned about 1.34% of COMPASS Pathways worth $5,762,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Logos Global Management LP increased its position in shares of COMPASS Pathways by 349.3% during the second quarter. Logos Global Management LP now owns 1,159,030 shares of the company's stock worth $7,001,000 after purchasing an additional 901,050 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of COMPASS Pathways by 1,518.4% during the 2nd quarter. Renaissance Technologies LLC now owns 263,800 shares of the company's stock worth $1,593,000 after purchasing an additional 247,500 shares during the last quarter. Hennion & Walsh Asset Management Inc. purchased a new stake in shares of COMPASS Pathways in the second quarter valued at approximately $664,000. Tidal Investments LLC increased its holdings in shares of COMPASS Pathways by 43.6% in the first quarter. Tidal Investments LLC now owns 19,082 shares of the company's stock valued at $159,000 after purchasing an additional 5,795 shares during the last quarter. Finally, Virtu Financial LLC purchased a new position in COMPASS Pathways during the first quarter worth approximately $201,000. Institutional investors and hedge funds own 46.19% of the company's stock.

Insider Activity at COMPASS Pathways

In related news, major shareholder Life Sciences N.V. Atai sold 2,660,000 shares of the business's stock in a transaction on Thursday, September 26th. The shares were sold at an average price of $6.05, for a total value of $16,093,000.00. Following the completion of the sale, the insider now directly owns 6,905,774 shares of the company's stock, valued at $41,779,932.70. The trade was a 27.81 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 4.25% of the stock is currently owned by corporate insiders.

COMPASS Pathways Stock Up 0.7 %

Shares of CMPS traded up $0.03 during midday trading on Friday, reaching $4.59. The stock had a trading volume of 368,948 shares, compared to its average volume of 631,434. The company has a debt-to-equity ratio of 0.15, a current ratio of 8.91 and a quick ratio of 8.91. The company's fifty day simple moving average is $5.68 and its two-hundred day simple moving average is $6.60. The company has a market cap of $314.05 million, a price-to-earnings ratio of -2.07 and a beta of 2.29. COMPASS Pathways plc has a 1-year low of $4.05 and a 1-year high of $12.75.

COMPASS Pathways (NASDAQ:CMPS - Get Free Report) last announced its quarterly earnings results on Thursday, October 31st. The company reported ($0.56) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.60) by $0.04. During the same period in the previous year, the company earned ($0.67) EPS. Equities research analysts expect that COMPASS Pathways plc will post -2.33 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on the company. Maxim Group lowered their price target on COMPASS Pathways from $22.00 to $12.00 and set a "buy" rating for the company in a research report on Friday, November 1st. HC Wainwright lowered their target price on COMPASS Pathways from $120.00 to $60.00 and set a "buy" rating for the company in a report on Friday, November 1st. Canaccord Genuity Group cut their price target on shares of COMPASS Pathways from $50.00 to $48.00 and set a "buy" rating on the stock in a research note on Friday, August 2nd. Cantor Fitzgerald restated an "overweight" rating on shares of COMPASS Pathways in a report on Monday, September 9th. Finally, Royal Bank of Canada reduced their target price on shares of COMPASS Pathways from $23.00 to $18.00 and set an "outperform" rating on the stock in a report on Friday, November 1st. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, COMPASS Pathways presently has an average rating of "Buy" and an average target price of $30.67.

COMPASS Pathways Profile

COMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa.